Pathophysiology and treatment of fatigue in multiple sclerosis;Physiopathologie et traitement de la fatigue dans la sclérose en plaques

Revue Neurologique

Volumn 162, Issue 3, 2006, Pages 311-320

  Boerio D ^a,b   Lefaucheur, J P ^a   Hogrel, J Y ^b   Creange A ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Central and peripheral nervous system; Evaluation; Fatigue; Immunology; Treatment

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMINOPYRIDINE DERIVATIVE; MODAFINIL; PEMOLINE;

ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DEPRESSION; DYSTHYMIA; FATIGUE; HUMAN; IMMUNOLOGICAL PARAMETERS; MENTAL TASK; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; REVIEW; TASK PERFORMANCE;

EID: 33645779981     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(06)75017-2     Document Type: Article

References (99)

1. ALLEN GM, GANDEVIA SC, MCKENZIE DK. (1995). Reliability of measurements of muscle strength and voluntary activation using twitch interpolation. Muscle Nerve, 18: 593-600.
2. ANTONINI G, MILLEFIORINI E, BORSELLINO G, MORINO S, RASURA M, POZZILLI C. (1995). Subclinical peripheral nervous system involvement in multiple sclerosis. Muscle Nerve, 18: 1216-1217.
3. ARNASON BG, TOSCAS A, DAYAL A, QU Z, NORONHA A. (1997). Role of interferons in demyelinating diseases. J Neural Transm, 49(Suppl): 117-123.
4. BAKSHI R, MILETICH RS, KINKEL PR, EMMET ML, KINKEL WR. (1998). High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging, 8: 228-234.
5. BAKSHI R, MILETICH RS, HENSCHEL K et al. (1999). Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology, 53: 1151-1153.
6. BAKSHI R, SHAIKH ZA, MILETICH RS et al. (2000). Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler, 6: 181-185.
7. BAKSHI R. (2003). Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler, 9: 219-227.
8. BARKER AT, JALINOUS R, FREESTON IL. (1985). Non-invasive magnetic stimulation of human motor cortex. Lancet, 1: 1106-1107.
9. BELZA BL, HENKE CJ, YELIN EH, EPSTEIN WV, GILLISS CL (1993). Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res, 42: 93-99.
10. BERGAMASCHI R, ROMANI M, VERSINO M, POLI R, COSI V. (1997). Clinical aspects of fatigue in multiple sclerosis. Funct Neurol, 12: 247-251.
11. BEVER CT Jr, YOUNG D, ANDERSON PA et al. (1994). The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology, 44: 1054-1059.
12. BIGLAND-RITCHIE B, JONES DA, HOSKING GP, EDWARDS RH. (1978). Central and peripheral fatigue in sustained maximum voluntary contractions of human quadriceps muscle. Clin Sci Mol Med, 54: 609-614.
13. BRANAS P, JORDAN R, FRY-SMITH A, BURLS A, HYDE C. (2000). Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess, 4: 1-61.
14. CALABRESI PA, FIELDS NS, FARNON EC et al. (1998). ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions. J Neuroimmunol, 85: 212-219.
15. CARAMIA MD, PALMIERI MG, DESIATO MT et al. (2004). Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation. Clin Neurophysiol, 115:956-965.
16. CELLA DF, DINEEN K, ARNASON B et al. (1996). Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology, 47: 129-139.
17. CHALDER T, BERELOWITZ G, PAWLIKOWSKA T, WATTS L, WESSELY S, WRIGHT D, WALLACE EP. (1993). Development of a fatigue scale. J Psychosom Res, 37: 147-153.
18. CODELLA M, ROCCA MA, COLOMBO B, MARTINELLI-BONESCHI F, COMI G, FILIPPI M. (2002). Cerebral grey matter pathology and fatigue in patients with multiple sclerosis: a preliminary study. J Neurol Sci, 194: 71-74.
19. COHEN RA, FISHER M. (1989). Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol, 46: 676-680.
20. COLOMBO B, MARTINELLI BONESCHI F, ROSSI P, ROVARIS M, MADERNA L, FILIPPI M, COMI G. (2000). MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. J Neurol, 247: 506-509.
21. COLOSIMO C, MILLEFIORINI E, GRASSO MG, VINCI F, FIORELLI M, KOUDRIAVTSEVA T, POZZILLI C. (1995). Fatigue in MS is associated with specific clinical features. Acta Neurol Scand, 92: 353-355.
22. COMI G, LEOCANI L, ROSSI P, COLOMBO B. (2001). Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol, 248: 174-179.
23. CRAIG J, YOUNG CA, ENNIS M, BAKER G, BOGGILD M. (2003). A randomized controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry, 74: 1225-1230.
24. DAVIE CA, HAWKINS CP, BARKER GJ, BRENNAN A, TOFTS PS, MILLER DH, MCDONALD WI. (1994). Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain, 117: 49-58.
25. DEBOUVERIE M, PITTION S, GUILLEMIN F, VESPIGNANI H. (2002). Echelles et classifications. Les échelles de fatigue utilisées au cours de la sclérose en plaques. Rev Neurol, 158: 1139-1143.
26. DE HAAN A, DE RUITER CJ, VAN DER WOUDE LH, JONGEN PJ. (2000). Contractile properties and fatigue of quadriceps muscles in multiple sclerosis. Muscle Nerve, 23: 1534-1541.
27. DE RUITER CJ, JONGEN PJ, VAN DER WOUDE LH, DE HAAN A. (2001). Contractile speed and fatigue of adductor pollicis muscle in multiple sclerosis. Muscle Nerve, 24: 1173-1180.
28. DI FABIO RP, SODERBERG J, CHOI T, HANSEN CR, SCHAPIRO RT. (1998). Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil, 79: 141-146.
29. DJALDETTI R, ZIV I, ACHIRON A, MELAMED E. (1996). Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology, 46: 632-635.
30. EISEN A, PATY D, HOIRCH M. (1982). Altered supernormality in multiple sclerosis peripheral nerve. Muscle Nerve, 5: 411-414.
31. FILIPPI M, ROCCA MA, COLOMBO B, FALINI A, CODELLA M, SCOTTI G, COMI G. (2002). Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. NeuroImage, 15: 559-567.
32. FISK J, PONTEFRACT A, RITVO PG, ARCHIBALD CJ, MURRAY TJ. (1994). The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci, 21: 9-14.
33. FLACHENECKER P, BIHLER I, WEBER F, GOTTSCHALK M, TOYKA KV, RIECKMANN P. (2004). Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler, 10: 165-169.
34. FREAL JE, KRAFT GH, CORYELL JK. (1984). Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil, 65: 135-138.
35. FORD H, TRIGWELL P, JOHNSON M. (1998). The nature of fatigue in multiple sclerosis. J Psychosom Res, 45: 33-38.
36. FUJIHARA K, MIYOSHI T. (1998). The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. J Neurol Sci, 159: 102-106.
37. GOEBEL MU, BAASE J, PITHAN V et al. (2002). Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects. Psychoneuroendocrinol, 27: 881-892.
38. GOTTSCHALK M, KUMPFEL T, FLACHENECKER P et al. (2005). Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol, 62: 277-280.
39. HOPF HC, EYSHOLDT M. (1978). Impaired refractory periods of peripheral sensory nerves in multiple sclerosis. Ann Neurol, 4: 499-501.
40. IRIARTE J, KATSAMAKIS G, DE CASTRO P. (1999). The fatigue descriptive scale (FDS): a usefull tool to evaluate fatigue in multiple sclerosis. Mult Scler, 5: 10-16.
41. IRIARTE J, SUBIRA ML, CASTRO P. (2000). Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Mult Scler, 2: 124-130.
42. JANARDHAN V, BAKSHI R. (2002). Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci, 205: 51-58.
43. KENT-BRAUN JA, SHARMA KR, WEINER MW, MILLER RG. (1994a). Effects of exercise on muscle activation and metabolism in multiple sclerosis. Muscle Nerve, 17: 1162-1169.
44. KENT-BRAUN JA, SHARMA KR, MILLER RG, WEINER MW. (1994b). Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis. Muscle Nerve, 17: 835-841.
45. KROENCKE DC, LYNCH SG, DENNEY DR. (2000). Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern. Mult Scler, 6: 131-136.
46. KRUPP LB, ALVAREZ LA, LAROCCA NG, SCHEINBERG LC. (1988). Fatigue in multiple sclerosis. Arch Neurol, 45: 435-437.
47. KRUPP LB, LAROCCA NG, MUIR-NASH J, STEINBERG AD. (1989). The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol, 46: 1121-1123.
48. KRUPP LB, COYLE PK, DOSCHER C et al. (1995). Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology, 45: 1956-1961.
49. KRUPP LB, POLLINA DA. (1996). Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol, 9: 456-460.
50. KRUPP LB, ELKINS LE. (2000). Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology, 55: 934-939.
51. KRUPP LB, CHRISTODOULOU C. (2001). Fatigue in multiple sclerosis. Curr Neurol Neurosci Rep, 1: 294-298.
52. KRUPP LB. (2003). Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs, 17: 225-234.
53. KUJALA P, PORTIN R, REVONSUO A, RUUTIAINEN J. (1995). Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry, 59: 77-82.
54. LAMBERT CP, ARCHER RL, EVANS WJ. (2000). Muscle strength and fatigue during isokinetic exercise in individuals with multiple sclerosis. Med Sci Sports Exerc, 33: 1613-1619.
55. LEE M, REDDY H, JOHANSEN-BERG H et al. (2000). The motor cortex shows adaptative functional changes to brain injury from multiple sclerosis. Ann Neurol, 47: 606-613.
56. LEOCANI L, COLOMBO B, MAGNANI G et al. Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement - EEG evidence. (2001). NeuroImage, 13: 1186-1192.
57. LERDAL A, CELIUS EG, MOUM T. (2003). Fatigue and its association with sociodemographic variables among multiple sclerosis patients. Mult Scler, 9: 509-514.
58. MAINERO C, FARONI J, GASPERINI C et al. (1999). Fatigue and magnetic resonance imaging activity in multiple sclerosis. J Neurol, 246: 454-458.
59. MAINERO C, INGHILLERI M, PANTANO P et al. (2004). Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology, 62: 2044-2050.
60. MARTINEZ-CACERES EM, RIO J, BARRAU M, DURAN I, BORRAS C, TINTORE M, MONTALBAN X. (1998). Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Ann Neurol, 44: 682-685.
61. MERTON PA. Voluntary strength and fatigue. (1954). J Physiol, 123: 553-564.
62. MILLER RG, GREEN AT, MOUSSAVI RS, CARSON PJ, WEINER MW. (1990). Excessive muscular fatigue in patients with spastic paraparesis. Neurology, 40: 1271-1274.
63. MILLER RG, MOUSSAVI RS, GREEN AT, CARSON PJ, WEINER MW. (1993). The fatigue of rapid repetitive movements. Neurology, 43: 755-761.
64. MURRAY T. Amantadine therapy for fatigue in multiple sclerosis. (1985). Can J Neurol Sci, 12: 251-254.
65. NIJS J, VAN DE VELDE B, DE MEIRLEIR K. (2005). Pain in patients with chronic fatigue syndrome: does nitric oxide trigger central sensitisation? Medical Hypotheses, 64: 558-562.
66. PANTANO P, IANNETTI GD, CARAMIA F et al. (2002). Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain, 125: 1607-1615.
67. PAUL RH, BEATTY WW, SCHNEIDER R, BLANCO C, HAMES K. (1998a). Impairments of attention in individuals with Multiple Sclerosis. Mult Scler, 4: 433-439.
68. PAUL RH, BEATTY WW, SCHNEIDER R, BLANCO C, HAMES K. (1998b). Cognitive and physical fatigue in multiple sclerosis: relations between self-report and objective performance. Appl Neuropsychol, 5: 143-148.
69. PETAJAN JH, GAPPMEIER E, WHITE AT, SPENCER MK, MINO L, HICKS RW. (1996). Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol, 39: 432-441.
70. PETAJAN JH, WHITE AT. (2000). Motor-evoked potentials in response to fatiguing grip exercise in multiple sclerosis patients. Clin Neurophysiol, 111: 2188-2195.
71. POLMAN CH, BERTELSMANN FW, DE WAAL R, VAN DIEMEN HA, UITDEHAAG BM, VAN LOENEN AC, KOETSIER JC. (1994). 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol, 51: 1136-1139.
72. RACKE MK, HAWKER K. (2004). Fatigue in multiple sclerosis. Is the picture getting simpler or more complex? Arch Neurol, 61: 176-177.
73. RAMMOHAN KW, ROSENBERG JH, LYNN DJ, BLUMENFELD AM, POLLAK CP, NAGARAJA HN. (2002). Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry, 72: 179-183.
74. REDDY H, NARAYANAN S, ARNOUTELIS R, JENKINSON M, ANTEL J, MATTHEWS PM, ARNOLD DL. (2000). Evidence for adaptative functional changes in the cerebtal cortex with axonal injury from multiple sclerosis. Brain, 123: 2314-2320.
75. RICE CL, VOLLMER TL, BIGLAND-RITCHIE B. (1992). Neuromuscular responses of patients with multiple sclerosis. Muscle Nerve, 15: 1123-1132.
76. ROCCA MA, FALINI A, COLOMBO B, SCOTTI G, COMI G, FILIPPI M. (2002). Adaptative functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. Ann Neurol, 51: 330-339.
77. 18F-fluorodeoxyglucose positron emission tomography study. Neurology, 48: 1566-1571.
78. ROSSINI PM, PASQUALETTI P, POZZILLI C et al. (2001). Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler, 7: 354-358.
79. RUDICK RA, BARNA BP. (1990). Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue. Arch Neurol, 47: 254-255.
80. SANDRONI P, WALKER C, STARR A. (1992). "Fatigue" in patients with multiple sclerosis. Motor pathway conduction and event-related potentials. Arch Neurol, 49: 517-524.
81. SCHUBERT M, WOHLFARTH K, ROLLNIK JD, DENGLER R. (1998). Walking and fatigue in multiple sclerosis: the role of the corticospinal system. Muscle Nerve, 21: 1068-1070.
82. SCHWARTZ JE, JANDORF L, KRUPP LB. (1993). The measurement of fatigue: a new instrument. J Psychosom Res, 37: 753-762.
83. SCHWARTZ CE, COULTHARD-MORRIS L, ZENG Q. (1996). Psychosocial correlates of fatigue in multiple sclerosis. Arch Phys Med Rehabil, 77: 165-170.
84. SCHWID SR, THORNTON CA, PANDYA S et al. (1999).Quantitative assessment of motor fatigue and strength in MS. Neurology, 53: 743-750.
85. SHARMA KR, KENT-BRAUN JA, MYNHIER MA, WEINER MW, MILLER RG. (1995). Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve, 18: 1403-1411.
86. SHEEAN GL, MURRAY NMF, ROTHWELL JC, MILLER DH, THOMPSON AJ. (1997). An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain, 120: 299-315.
87. SHEEAN GL, MURRAY NMF, ROTHWELL JC, MILLER DH, THOMPSON AJ. (1998). An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain, 121: 967-975.
88. SMETS EM, GARSSEN B, BONKE B, DE HAES JC. (1995). The Multi-dimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res, 39: 315-325.
89. SMITH KJ, FELTS PA, JOHN GR. (2000). Effects of 4-aminopyrodine on demyelinated axons, synapses and muscle tension. Brain, 123: 171-184.
90. STANKOFF B, WAUBANT E, CONFAVREUX et al. (2005). Modafinil for the treatment of fatigue in multiple sclerosis : a randomized placebo-controlled double blind study. Neurology, 64:1139-1143.
91. TARTAGLIA MC, NARAYANAN S, FRANCIS SJ, CARLOS SANTOS A, DE STEFANO N, LAPIERRE Y, ARNOLD DL. (2004a). The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol, 61: 201-207.
92. TARTAGLIA MC, NARAYANAN S, ARNOLD DL. (2004b). Fatigue in multiple sclerosis is associated with an altered pattern and increased volume of cerebral activation. Poster: P 04.45 American Academy of Neurology, San Francisco. Neurology, 62 Suppl 5: A294.
93. VAN DER WERF SP, JONGEN PJ, LYCKLAMA A NIJEHOLT GJ, BARKHOF F, HOMMES OR, BLEIJENBERG G. (1998). Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci, 160: 164-170.
94. VERCOULEN JH, HOMMES OR, SWANINK CM et al. (1996). The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol, 53: 642-649.
95. VOUYOVITCH-PITTION S. (2001). Validation d'une échelle de fatigue de la sclérose en plaques. Thèse de Médecine, Nancy no 28.
96. WARE JJ, SHERBOURNE CD. (1992). The MOS 36-itemss short-form health survey (SF-36). I. Conceptual framework and item selection. Medical care, 30: 473-483.
97. WAXMAN SG. (1982). Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med, 306: 1529-1533.
98. WEINSHENKER BG, PENMAN M, BASS B, EBERS GC, RICE GP. (1992). A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology, 42: 1468-1471.
99. ZIFKO UA, RUPP M, SCHWARZ S, ZIPKO HT, MAIDA EM. (2002). Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol, 249: 983-987.